Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial

Basit Öğe Kaydı
dc.contributor.authorYalcin, K
dc.contributor.authorAcar, M
dc.contributor.authorDegertekin, H
dc.date.accessioned2024-04-24T16:10:38Z
dc.date.available2024-04-24T16:10:38Z
dc.date.issued2003
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Hepatitis B virus (HBV) vaccine therapy has two major areas of application: for preventive purposes and for treating patients with chronic hepatitis B. This study aimed to investigate the effect of therapeutic vaccination of inactive hepatitis B surface antigen (HbsAg) carriers using a recombinant hepatitis B vaccine in a randomized-controlled study. Patients and Methods: The 71 studied patients had never received prior antiviral therapies, were anti-HBe positive, had undetectable HBV-DNA and persistently normal alanine transaminase levels. 31 patients were given three 20 mg intramuscular injections of a preS2/S vaccine (GenHevac-B) on days 0, 30 and 60 and the remaining 40 patients were included in the control group. The efficacy of vaccination was evaluated by testing for HBsAg seroconversion to anti-HBs. Post-vaccination follow-up was for 12 months after the first dose. Results: At the end of the follow-up, three out of 31 patients (10%) who received vaccine therapy were able to clear HBsAg from their sera and concomitantly develop anti-HBs antibodies. In contrast, none of the 40 control patients who did not received vaccine therapy had decreased their levels of HBsAg or elicited anti-HBs antibodies (p = 0.079). In three vaccinated patients serum HBsAg became undetectable approximately by the 3rd month of vaccine therapy and HBsAg seroconversion was seen to be durable in all patients in the follow-up period. Conclusion: This study offers the first direct evidence, based on a controlled study, that the recombinant HBV vaccine has no great effect in enhancing the rate of HBsAg seroconversion in inactive HBsAg carriers. More efficient strategies, such as an increase in the dose and number of immunizations, should be evaluated further in large controlled trials.en_US
dc.identifier.doi10.1007/s15010-003-3187-1
dc.identifier.endpage225en_US
dc.identifier.issn0300-8126
dc.identifier.issue4en_US
dc.identifier.pmid14562945
dc.identifier.scopus2-s2.0-0041657605
dc.identifier.scopusqualityQ1
dc.identifier.startpage221en_US
dc.identifier.urihttps://doi.org/10.1007/s15010-003-3187-1
dc.identifier.urihttps://hdl.handle.net/11468/14982
dc.identifier.volume31en_US
dc.identifier.wosWOS:000184792400005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherMmv Medien & Medizin Verlagsgesellschaft Mbhen_US
dc.relation.ispartofInfection
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleSpecific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trialen_US
dc.titleSpecific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu